Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Intrabone Delivery of CD34+ Cells Using an Optimized Delivery System Does Not Enhance Engraftment in a Rhesus Macaque Model of Hematopoietic Stem Cell Transplantation

Blood (2018) 132 (Supplement 1): 5677.

https://doi.org/10.1182/blood-2018-99-114730

Published: 2018

Journal Articles

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Brian GM Durie, MD, Antje Hoering, PhD, Rachael Sexton, PhD, Muneer H. Abidi, MD, Joshua Epstein, DSc, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J. Reu, MD, Christopher M. Reynolds, MD, Robert Z. Orlowski, MD PhD, Bart Barlogie, MD PhD

Blood (2018) 132 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2018-99-117003

Published: 2018

Journal Articles

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

Andrei Shustov, MD, Patrick B Johnston, MD PhD, Stefan Klaus Barta, MDMRCP,MS, Gajanan Bhat, Guru Reddy, Yasuhiro Oki, MD

Blood (2017) 130 (Supplement 1): 818.

https://doi.org/10.1182/blood.V130.Suppl_1.818.818

Published: 2017

Journal Articles

CHOP in Combination with Pralatrexate, a Novel Folate Analogue Metabolic Inhibitor in Patients with Previously Untreated Peripheral T-Cell Lymphoma (PTCL): Interim Results of the Phase 1 Trial

Andrei R. Shustov, MD, Yasuhiro Oki, MD, Stefan Klaus Barta, MD MRCP, MS, Patrick B. Johnston, MD PhD, Pankaj Sharma, Tao Song, Sanjay Mourya

Blood (2016) 128 (22): 5355.

https://doi.org/10.1182/blood.V128.22.5355.5355

Published: 2016

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Brian Durie, MD, Antje Hoering, PhD, S. Vincent Rajkumar, MD, Muneer H. Abidi, MD, Joshua Epstein, DSc, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J Reu, Christopher M. Reynolds, MD, Rachael Sexton, MS, Robert Z. Orlowski, PhD, MD, Bart Barlogie, MD PhD, Angela Dispenzieri, MD

Blood (2015) 126 (23): 25.

https://doi.org/10.1182/blood.V126.23.25.25

Published: 2015

Journal Articles

Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics

Blood (2015) 126 (23): 2501.

https://doi.org/10.1182/blood.V126.23.2501.2501

Published: 2015

Journal Articles

Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma

Madeleine Duvic, MD, Steven M Horwitz, MD, Youn H Kim, MD, Pier Luigi Zinzani, Gajanan Bhat, PhD, Pankaj Sharma, Sue Yancik

Blood (2015) 126 (23): 2677.

https://doi.org/10.1182/blood.V126.23.2677.2677

Published: 2015

Journal Articles

An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment

Kevin R. Kelly, MD PhD, Nashat Y. Gabrail, MD, William J Edenfield, MD, A Craig Lockhart, Anthony J. Olszanski, MDPhD, Guru Reddy

Blood (2015) 126 (23): 3966.

https://doi.org/10.1182/blood.V126.23.3966.3966

Published: 2015

Journal Articles

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

Reed Friend, MD, Ridas Juskevicius, MD, Lauren Salmon, DO, Hemant S. Murthy, MD, James Xenakis, Adam S. Asch, MD, Paul Walker, MD

Blood (2015) 126 (23): 3783.

https://doi.org/10.1182/blood.V126.23.3783.3783

Published: 2015

Journal Articles

To Push or Not to Push: The Benefit of Administering Anti-Emetics By Intravenous Push

Arun Kumar Arumugam Raajasekar, MBBS, Sindhu Barola, MBBS, Lynne Tehrani, CNS, Abhinav B Chandra, MD MSc, FACP

Blood (2015) 126 (23): 3314.

https://doi.org/10.1182/blood.V126.23.3314.3314

Published: 2015

Journal Articles

NKTT120 Safely Depletes iNKT Cells in Stable Adult Sickle Cell Patients in a Phase 1 Trial

Joshua J. Field, MD MS, Elaine M. Majerus, MD PhD, Ken I. Ataga, MD, Elliott P. Vichinsky, MD, Cheryl Eaton, Rosemary Mazanet, MD PhD, David G. Nathan, MD

Blood (2015) 126 (23): 2178.

https://doi.org/10.1182/blood.V126.23.2178.2178

Published: 2015

Journal Articles

Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ

Gertjan Kaspers, MD PhD, Denise Niewerth, MSc, Satianand Ramnarain, MSc, Andishe Attarbaschi, MD, André Baruchel, MD, Evelina S De Bont, MDPhD, Franca Fagioli, MD, Barbara De Moerloose, MD PhD, Karsten Nysom, MD, Giuseppe Palumbo, MD, Dirk Reinhardt, MD PhD, Pierre-Simon Rohrlich, MDPhD, Pauline Simon, MD, Arend von Stackelberg, MD, C. Michel Zwaan, MD PhD

Blood (2014) 124 (21): 2290.

https://doi.org/10.1182/blood.V124.21.2290.2290

Published: 2014

Journal Articles

Phase II study of 90 y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma

Jesus C Fabregas, MD, James E. Hoffman, MD, Tulay Koru-Sengul, PhD, Miao Feng, Deborah Goodman, Aldo Serafini, MD, Peter J Hosein, MD, Alexandra Stefanovic, MD, Joseph D. Rosenblatt, MD, Izidore S. Lossos, MD

Blood (2014) 124 (21): 1762.

https://doi.org/10.1182/blood.V124.21.1762.1762

Published: 2014

Journal Articles

A Single Center Experience With Pralatrexate Alone Or In Combination With Bexarotene: Long Term Responses In Advanced Stage Relapsed/Refractory Cutaneous T-Cell Lymphoma

Rakhshandra Talpur, MD, Andrew Thompson, Pamela Gangar, Madeleine Duvic, MD

Blood (2013) 122 (21): 5113.

https://doi.org/10.1182/blood.V122.21.5113.5113

Published: 2013

Journal Articles

High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)

Danielle Sterrenberg, MD, Patrick J Stiff, MD, Mala Parthasarathy, MS, Aileen Go, MD, Scott E. Smith, MD, PhD, Tulio E. Rodriguez, MD

Blood (2013) 122 (21): 3376.

https://doi.org/10.1182/blood.V122.21.3376.3376

Published: 2013

Journal Articles

Sickle Cell Crisis: Safety Of a High-Dose Opioid Protocol In The Emergency Department

Paula Tanabe, PhD, RN, FAEN, FAAN, Judith Paice, PhD, RN, FAAN, Zoran Martinovich, PhD, Laura M. De Castro, MD

Blood (2013) 122 (21): 5579.

https://doi.org/10.1182/blood.V122.21.5579.5579

Published: 2013

Journal Articles

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Gertjan Kaspers, MD, PhD, Ron Mathot, PharmD PhD, Satianand Ramnarain, MSc, Denise Niewerth, MSc, Franco Locatelli, MD, PhD, Eveline S.J.M De Bont, MD, PhD, Franca Fagioli, MD, Pierre Rohrlich, MD, Arend von Stackelberg, Michel Zwaan

Blood (2013) 122 (21): 1439.

https://doi.org/10.1182/blood.V122.21.1439.1439

Published: 2013

Journal Articles

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Beata Holkova, MD, Edward B. Perkins, MD, PhD, Prithviraj Bose, MD, Daniel M Sullivan, MD, Rachid Baz, MD, Mary Beth Tombes, RN, Ellen Shrader, Viswanathan Ramakrishnan, PhD, Wen Wan, PhD, Heidi Sankala, PhD, Maciej Kmieciak, PhD, John D. Roberts, MD, Steven Grant, MD

Blood (2012) 120 (21): 2959.

https://doi.org/10.1182/blood.V120.21.2959.2959

Published: 2012

Journal Articles

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

William I. Bensinger, MD, Pamela S Becker, MD, PhD, Ted A. Gooley, PhD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Robert Vescio, MD, Ajay K. Gopal, MD, Damian J. Green, MD, Oliver W. Press, MD, PhD, Michael Lill, M.D., Leona Holmberg, MD, PhD, Jainulabdeen J Ifthikharuddin, MD, Gordon L. Phillips, II, MD

Blood (2012) 120 (21): 2009.

https://doi.org/10.1182/blood.V120.21.2009.2009

Published: 2012

Journal Articles

Fatal Thrombotic Microangiopathy Developing within 24 Hours of Carfilzomib in a Patient with Relapsed Multiple Myeloma (MM)

Shebli Atrash, MD, Amy Joiner, K, MD, Bart Barlogie, MD, PHD, Stephen Medlin, DO, FACP

Blood (2012) 120 (21): 5037.

https://doi.org/10.1182/blood.V120.21.5037.5037

Published: 2012

NARROW

Intrabone Delivery of CD34+ Cells Using an Optimized Delivery System Does Not Enhance Engraftment in a Rhesus Macaque Model of Hematopoietic Stem Cell Transplantation

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Pralatrexate in Combination with Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Phase 1 Dose-Escalation Study

CHOP in Combination with Pralatrexate, a Novel Folate Analogue Metabolic Inhibitor in Patients with Previously Untreated Peripheral T-Cell Lymphoma (PTCL): Interim Results of the Phase 1 Trial

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Phase II Study on Bortezomib (BTZ) in Multiple Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (rALL): High Response Rate with a Modestly Intensive Regimen Including BTZ, Not Related to Pharmacokinetics

Results from a Phase 1/2, Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma

An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment

Phase II Trial Daily Pulse Interleukin-2 Therapy with Famotidine during Marrow and Lymphocyte Recovery in Acute Myeloid Leukemia: LJCC 0605

To Push or Not to Push: The Benefit of Administering Anti-Emetics By Intravenous Push

NKTT120 Safely Depletes iNKT Cells in Stable Adult Sickle Cell Patients in a Phase 1 Trial

Results of a Feasibility and Phase II Study on Bortezomib (BTZ) in Pediatric Multiply Relapsed or Refractory Acute Lymphoblastic Leukemia: Complete Hematological Responses with a Modestly Intensive Regimen Including BTZ

Phase II study of 90 y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma

A Single Center Experience With Pralatrexate Alone Or In Combination With Bexarotene: Long Term Responses In Advanced Stage Relapsed/Refractory Cutaneous T-Cell Lymphoma

High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)

Sickle Cell Crisis: Safety Of a High-Dose Opioid Protocol In The Emergency Department

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory Indolent B-Cell Neoplasms - Update of the “Bolus” Infusion Schedule of Alvocidib.

Randomized Comparison of Melphalan 200 Mg/m 2 v. 280 Mg/m 2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Fatal Thrombotic Microangiopathy Developing within 24 Hours of Carfilzomib in a Patient with Relapsed Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only